- Home
- PRG vs SLBT Comparison
PRG vs SLBT Comparison
Compare PRG & SLBT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRG | SLBT |
|---|---|---|
| Founded | 2020 | N/A |
| Country | United States | Taiwan |
| Employees | N/A | N/A |
| Industry | Diversified Commercial Services | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.5B |
| IPO Year | 2020 | 2025 |
Fundamental Metrics
Financial Performance| Metric | PRG | SLBT |
|---|---|---|
| Price | $39.49 | $2.93 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $50.00 | N/A |
| AVG Volume (30 Days) | ★ 431.0K | 40.2K |
| Earning Date | 04-29-2026 | N/A |
| Dividend Yield | ★ 1.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $2,409,223,000.00 | N/A |
| Revenue This Year | $23.77 | N/A |
| Revenue Next Year | $7.91 | N/A |
| P/E Ratio | $21.51 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $25.80 | $2.51 |
| 52 Week High | $47.73 | $6.25 |
Technical Indicators
Market Signals| Indicator | PRG | SLBT |
|---|---|---|
| Relative Strength Index (RSI) | 39.71 | 53.68 |
| Support Level | $38.13 | $2.52 |
| Resistance Level | $41.14 | $3.40 |
| Average True Range (ATR) | 1.15 | 0.19 |
| MACD | -0.15 | 0.10 |
| Stochastic Oscillator | 26.57 | 70.63 |
Price Performance
Historical ComparisonAbout PRG PROG Holdings Inc.
PROG Holdings Inc is a financial technology holding company that provides transparent and competitive payment options to consumers. The company has two reportable segments: Progressive Leasing, an in-store, app-based, and e-commerce point-of-sale lease-to-own solutions provider; and Vive Financial (Vive), an omnichannel provider of second-look revolving credit products. The majority of the revenue of the company is earned through the Progressive Leasing segment.
About SLBT SL Science Holding Limited Ordinary Shares
SL Science Holding Ltd is a biomedical company specialized in developing cellular and gene therapies advancing regenerative medicine and cancer treatment. It utilizes immune stem cells to target cancer and bovine-derived milk exosomes to regenerate damaged tissues, thus potentially offering expansive medical applications for its products. With proprietary technologies such as Armed-T and Gamma Delta T cells, as well as exosome applications in skincare and cancer recovery. It operates in three segments namely Exosome products, CD-19 Armed-T products, and GDT cell therapy products. It derives revenue from Exosome products segment.